PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

MHRA starts rolling review of AZ’s coronavirus vaccine

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has started an accelerated or rolling review of AstraZeneca’s coronavirus vaccine candidate, the British pharma giant confirmed on Sunday.

Regulators will be able to review data in real time under a rolling review process, which is designed to help speed up the approval timeline of potential vaccines for the novel coronavirus, which causes COVID-19.

On Sunday, an AZ spokesman told Reuters: “We confirm the MHRA’s review of our potential COVID-19 vaccine.”

AZ is developing its COVID-19 vaccine, AZD1222, with the University of Oxford, and the shot is currently being studied in a large-scale phase III clinical trial programme.

It uses a replication-deficient chimpanzee viral vector based on a weakened version of an adenovirus (the common cold virus) that contains the genetic material of SARS-CoV-2 virus spike protein, which causes COVID-19.

The MHRA has also started a rolling review of Moderna’s mRNA-based vaccine candidate, while Bloomberg also reported last week that the agency has started an accelerated review of Pfizer and BioNTech’s potential COVID-19 vaccine.

AZ said in a statement earlier this month that results from the phase III trials are expected later this year, depending on the COVID-19 infection rate in the communities where the studies are being conducted.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026